The specific goals of the proposed work are to (a) directly identify opioid delta receptor subtypes in brain and other tissues using radioligand binding techniques in wholebrain control membranes, in membranes pretreated with selective and irreversible ligands, in membranes from different strains of mice which have been reported to show differences in populations of opioid receptors (e.g., the mu-receptor deficient CXBK mouse), and in membranes from specific brain regions; (b) investigate possible differences in the regulation of interactions of the receptor subtypes with their respective effector systems by evaluation of radioligand binding in the presence of guanine nucleotides, cations (or both), or following pretreatment with pertussis toxin in vitro or in vivo; (c) use radioligand binding techniques to evaluate possible mechanism of tolerance and supersensitivity following repeated/continuous exposure of the brain to compounds with selectivity for the opioid delta receptor subtypes, and (d) use some of the above approaches in an effector system by measuring adenylyl cyclase activity in NG 108-15 cells. Such approaches will provide insights into opioid delta subtypes, and their mechanisms which may correlate with substantial data accumulated in vivo, and may be important in establishing the potential therapeutic utility of delta subtype selective drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
1K02DA000185-01
Application #
3069564
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1993-03-01
Project End
1998-02-28
Budget Start
1993-03-01
Budget End
1994-02-28
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lai, J; Crook, T J; Payne, A et al. (1997) Antisense targeting of delta opioid receptors in NG 108-15 cells: direct correlation between oligodeoxynucleotide uptake and receptor density. J Pharmacol Exp Ther 281:589-96
Zaki, P A; Bilsky, E J; Vanderah, T W et al. (1996) Opioid receptor types and subtypes: the delta receptor as a model. Annu Rev Pharmacol Toxicol 36:379-401
Bilsky, E J; Bernstein, R N; Hruby, V J et al. (1996) Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated ""knock-down"" of opioid receptor in vivo. J Pharmacol Exp Ther 277:491-501
Bilsky, E J; Bernstein, R N; Wang, Z et al. (1996) Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277:484-90
Nichols, M L; Bian, D; Ossipov, M H et al. (1996) Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins. Neurosci Lett 215:161-4
Mayfield, K P; Horvath, R; Lai, J et al. (1995) Increased expression of opioid delta receptors by deoxy conformation heme proteins in NG108-15 cells. Brain Res 676:358-62
Reid, L D; Glick, S D; Menkens, K A et al. (1995) Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 6:1409-12
Vanderah, T W; Lai, J; Yamamura, H I et al. (1994) Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole- and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception. Neuroreport 5:2601-5
Horan, P J; Mattia, A; Bilsky, E J et al. (1993) Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Pharmacol Exp Ther 265:1446-54
Horan, P J; de Costa, B R; Rice, K et al. (1993) Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. J Pharmacol Exp Ther 266:926-33

Showing the most recent 10 out of 12 publications